IGKV1D-42: A Potential Drug Target and Biomarker (G28892)

Target Name: IGKV1D-42

NCBI ID: G28892

Other Name(s): IGKV1D42 | Immunoglobulin kappa variable 1D-42 (non-functional) | L22 | immunoglobulin kappa variable 1D-42 (non-functional)

IGKV1D-42: A Potential Drug Target and Biomarker

The IGKV1D-42 gene has been identified as a potential drug target and biomarker for several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. IGKV1D-42 is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including gene expression, DNA replication, and repair. In recent years, researchers have been investigating the potential clinical applications of IGKV1D-42 as a drug target and biomarker. In this article, we will review the current research on IGKV1D-42 and its potential as a drug target and biomarker.

Potential Drug Target

IGKV1D-42 has been shown to be involved in several signaling pathways that are involved in the development and progression of various diseases. One of the most promising aspects of IGKV1D-42 as a drug target is its involvement in the development of neurodegenerative disorders. Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of progressive symptoms. IGKV1D-42 has been shown to be involved in the regulation of cellular processes that are essential for the maintenance of brain health, including the replication of damaged DNA and the regulation of gene expression.

In addition to its involvement in neurodegenerative disorders, IGKV1D-42 has also been shown to be involved in the development of cancer. Cancer is a complex disease that is characterized by the rapid growth and proliferation of cells that can eventually form tumors. IGKV1D-42 has been shown to play a role in the regulation of cell division and the apoptosis, which are critical processes that are essential for the development and progression of cancer.

Potential Biomarker

IGKV1D-42 has also been shown to be involved in the regulation of cellular processes that are essential for the maintenance of cellular health and function. One of the most promising aspects of IGKV1D-42 as a biomarker is its ability to serve as a marker for the early detection of diseases. IGKV1D-42 has been shown to be involved in the regulation of cellular processes that are essential for the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

In addition to its potential as a drug target, IGKV1D-42 has also been shown to be a potential biomarker for several diseases. For example, IGKV1D-42 has been shown to be involved in the regulation of the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. IGKV1D-42 has also been shown to be involved in the regulation of the development and progression of cancer, including breast, ovarian, and colorectal cancers.

Conclusion

IGKV1D-42 is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including gene expression, DNA replication, and repair. In recent years, researchers have been investigating the potential clinical applications of IGKV1D-42 as a drug target and biomarker. The potential of IGKV1D-42 as a drug target and biomarker is based on its involvement in several signaling pathways that are involved in the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Further research is needed to fully understand the potential clinical applications of IGKV1D-42.

Protein Name: Immunoglobulin Kappa Variable 1D-42 (non-functional)

Functions: Probable non-functional open reading frame (ORF) of V region of the variable domain of immunoglobulin light chains (PubMed:24600447). Non-functional ORF generally cannot participate in the synthesis of a productive immunoglobulin chain due to altered V-(D)-J or switch recombination and/or splicing site (at mRNA level) and/or conserved amino acid change (protein level) (PubMed:9619395). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets